Fig. 4From: Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinomaKaplan-Meier plots of TTR (upper row) and OS (lower row) according to PODXL expression in patients treated with: (a, d) neoadjuvant ± adjuvant chemotherapy NOS, (b, e) neoadjuvant fluoropyrimidine and oxaliplatin ≥ 8 weeks ± adjuvant chemotherapy NOS, no irinotecan, or (c, f) surgery onlyBack to article page